USP39 and EphA2 expression in breast cancer before and after trastuzumab treatment and their correlation with the pathological characteristics of tumor

• Main Authors: Li-Ping Shen1, Kun Wang2
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2017-05-01
• Series: Journal of Hainan Medical University
• Subjects: Breast cancer Trastuzumab Human epidermal growth factor receptor-2 Ubiquitin-specific protease 39 Eph receptor tyrosine kinase A2
• Online Access: http://www.hnykdxxb.com/PDF/201710/30.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To study the USP39 and EphA2 expression in breast cancer before and after trastuzumab treatment and their correlation with the pathological characteristics of tumor. Methods: Breast cancer tissues before and after trastuzumab treatment between May 2013 and September 2016 were collected, the expression levels of USP39 and EphA2 as well as antiproliferation genes and pro-invasion genes in breast cancer were determined, and the quartile of USP39 and EphA2 expression after treatment were calculated. Results: USP39, EphA2, Sam68 and Gab2 mRNA expression in breast cancer after treatment were significantly lower than those those before treatment while ALEX1, PTPN14 and ARID1A mRNA expression were significantly higher than those before treatment; ALEX1, PTPN14, ARID1A, Sam68 and Gab2 mRNA expression in breast cancer with different USP39 and EphA2 expression were significantly different; the higher the USP39 and EphA2 mRNA expression, the lower the ALEX1, PTPN14 and ARID1A expression, and the higher the Sam68 and Gab2 expression. Conclusion: Trastuzumab therapy can influence the malignant biological behavior and pathological characteristics of tumor through inhibiting the expression of USP39 and EphA2.